Foveal thinning in neuromyelitis optica
A sign of retinal astrocytopathy?
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published April 11, 2017.
Author Disclosures
- Takashi Yamamura, MD, PhD and
- Ichiro Nakashima, MD, PhD
- Takashi Yamamura, MD, PhD and
(1)Biogen Japan (2) Chugai Pharmaceutical Co., Ltd (3) Takeda Pharamaceutical Co.
NONE
(1) Novartis Pharma (2) Nihon Pharmaceutical Co., Ltd., (3) Santen Pharmaceutical Co., Ltd., (4) Abbott Japan Co., Ltd./Eisai Co., Ltd., (5) Biogen Japan, (6) Dainippon Sumitomo Pharma Co., Ltd., (7) Bayer Holding Ltd., (8) Astellas Pharma Inc. (9) Takeda Pharamaceutical Co.
Clinical and Experimental Neuroimmunology, Editor, since 2010
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Ono Pharmaceutical Co., Ltd., (2) Chugai Pharmaceutical Co., Ltd., (3) Teva Pharmaceutical K.K., (4) Mitsubishi Tanabe Pharma Corporation, (5) Asahi Kasei Kuraray Medical CO., Ltd.
(1) Ministry of Health, Labour and Welfare of Japan, the Health and Labour Sciences Research Grants on Intractable Diseases (Neuroimmunological Diseases), investigator, since 2010.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ichiro Nakashima, MD, PhD
NONE
NONE
Received funding for a trip and speaks from Mitsubishi Tanabe Pharma (2012-2016) and Novartis Pharma (2012-2015).
Served as an editorial board member of Multiple Sclerosis International(2010-present).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Received grant support from LSI Medience Corporation (2012-2016).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the National Institute of Neuroscience (T.Y.), NCNP, Kodaira, Tokyo; and Department of Neurology (I.N.), Tohoku University School of Medicine, Aoba-ku, Sendai, Japan.
- Correspondence to Dr. Yamamura: yamamura{at}ncnp.go.jp
Article usage
Cited By...
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.